In a patient with acute leukemia, immunophenotype pattern is CD 19+ve, CD 10+ve, CD33+ve, CD13+ve. He may probably have:
CD19 is a B-cell marker, so if CD19 is positive, it points towards B-cell lineage. CD10 is also associated with B-cell ALL, particularly common in precursor B-cell ALL. CD33 and CD13 are myeloid markers, but wait, if the B-cell markers are positive, why are myeloid markers also present? Hmm, maybe it's a biphenotypic or mixed lineage leukemia? Or perhaps the question is testing if I know that some ALL cases can have myeloid markers as well?
Wait, in some cases of B-cell ALL, especially in adults, there can be co-expression of myeloid markers like CD13 and CD33. However, the key here is the presence of CD19 and CD10, which are more specific for B-cell lineage. CD10 is a hallmark of B-ALL. So the primary diagnosis would still be B-cell ALL, even if there are some myeloid markers. The options might include B-ALL with myeloid markers versus AML. But the question is asking which type the patient probably has. So the presence of CD19 and CD10 would make it more likely to be B-cell ALL.
Looking at the options again (though they aren't listed here), the correct answer would be B-cell ALL. The other options would be AML (which lacks CD19 and CD10), or maybe T-cell ALL (which would have CD7, CD2, etc.), or maybe a biphenotypic leukemia. But since CD19 is positive, it's B-cell. The presence of CD13 and CD33 might be a red herring, but they don't rule out B-ALL. Sometimes, especially in mixed lineage cases, there's co-expression, but the primary lineage is determined by the key markers. So the answer is B-cell ALL.
**Core Concept**
This question tests knowledge of immunophenotyping in acute leukemia. CD19 and CD10 are B-cell lineage markers, while CD33 and CD13 are myeloid markers. Their co-expression suggests a hybrid or lineage-specific diagnosis, with CD19/CD10 strongly indicative of B-cell acute lymphoblastic leukemia (B-ALL).
**Why the Correct Answer is Right**
The patient’s CD19+ and CD10+ profile confirms B-cell lineage, aligning with **B-cell acute lymphoblastic leukemia (B-ALL)**. CD10 is a hallmark of precursor B-ALL, particularly in childhood cases. While CD33 and CD13 are myeloid markers, their presence does not override the B-cell lineage determination. B-ALL can occasionally express myeloid antigens (e.g., CD13/CD33) due to cross-lineage contamination or maturation arrest.
**Why Each Wrong Option is Incorrect**
**Option A:** T-ALL lacks CD19 and CD10; instead, it expresses CD2, CD3, and CD7